PhONEME - ParticipatOn Ehealth MobilE. Effects of an Interactive ICT-platform for Assessment and Management of Symptoms in Patients Treated for Breast Cancer.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Karolinska Institutet
- Enrollment
- 150
- Locations
- 1
- Primary Endpoint
- Questionnaire Scale for Functional Health Literacy (S-FHL-Swedish version)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the effects of an interactive Information and Communication Technologies (ICT) -platform for use in a smartphone or tablet in patients treated with neoadjuvant chemotherapy for breast cancer. The hypothesis is that clinical management will be improved and costs reduced and safe and participatory care promoted, when patients report symptoms in an application which provides self-care advice and instant access to professionals.
Investigators
Ann Langius-Eklöf
RN, PhD, Professor
Karolinska Institutet
Eligibility Criteria
Inclusion Criteria
- •The diagnosis of breast cancer
- •Patients who will receive neoadjuvant chemotherapy
- •Literacy in the Swedish language
Exclusion Criteria
- •Patients who need an interpreter at the doctor's visit
- •Patients who have a known severe cognitive impairment
Outcomes
Primary Outcomes
Questionnaire Scale for Functional Health Literacy (S-FHL-Swedish version)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of understanding health
Questionnaire Scale for Communicative and Critical Health Literacy (S-C & C HL - Swedish version)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of communicating health
Questionnaire Individualized Care Scale (ICS)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of individualized care
Questionnaire Sense of Coherence Scale (KASAM)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of Sense of Coherence
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of health related quality of life
Questionnaire Memorial Symptom Assessment Scale (MSAS)
Time Frame: Up to 3 months after completion of neoadjuvant chemotherapy treatment
To evaluate self-reported data in terms of symptom prevalence, characteristics and distress
Secondary Outcomes
- Health care costs(Up to 3 months after completion of neoadjuvant chemotherapy treatment)